Drug Discovery Today

MARCH 1, 2022

People suffering from COVID-19 could have several different SARS-CoV-2 variants hidden away from the immune system in different parts of the body, finds new research published in Nature Communications by an international research team. The study’s authors say that this may make complete clearance of the virus from the body of an infected person, by their own antibodies, or by therapeutic antibody treatments, much more difficult.

Virus 100

Virus Research International Treatment 100

Drug Channels

MARCH 1, 2022

The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for TEKTURNA+HCT Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Noden Pharma drug TEKTURNA HCT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 94

Drugs Marketing 94

PerkinElmer

MARCH 4, 2022

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central or peripheral nervous system. Millions of people are affected by these conditions across the globe, and with improved life expectancy in many parts of the world, it is likely that incidence will increase in the future.

Regulations 52

Regulations Disease Research Engineering 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

The Pharma Data

MARCH 3, 2022

Use of the drug verapamil to treat Type 1 diabetes continues to show benefits lasting at least two years, researchers report in the journal Nature Communications. Patients taking the oral blood pressure medication not only required less daily insulin two years after first diagnosis of the disease, but also showed evidence of surprising immunomodulatory benefits.

RNA 52

RNA Treatment Disease Regulations 52

Drug Channels

MARCH 4, 2022

Today’s guest post comes from Miranda Gill, Vice President of Network at CoverMyMeds. Miranda discusses how integrated technology solutions can be used at critical moments in the patient’s journey to increase access, affordability, and adherence to therapies. To learn more about CoverMyMeds’ prescription decision support tools for the entire care team, visit CoverMyMeds at HIMSS22.

Therapies 82

Therapies Drugs 82

PerkinElmer

FEBRUARY 28, 2022

In early 2019, no one could have predicted that a novel coronavirus would sweep around the globe and cause one of the most significant health crises of recent times. Fast-forward to today, and thousands of scientists have turned their attention to studying SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. This research pivot led to a torrent of scientific papers describing the structure and biology of the virus being published.

Virus 52

Virus Vaccine Clinical Trials Treatment 52

The Pharma Data

MARCH 3, 2022

Multiple Sclerosis Journal has published data from the ALITHIOS open-label extension study which provide a robust picture of the continuous safety data for Kesimpta, showing it was well tolerated in ~2000 patients with up to 3.5 years exposure with no new safety risks identified 1 Immunoglobulin G (IgG) levels remained stable in patients treated up to 3.5 years and mean immunoglobulin M (IgM) levels decreased yet remained above the lower limit of normal in most patients treated with Kesimpta 1 L

Therapies 52

Therapies Treatment Vaccine Licensing 52

Drug Channels

MARCH 1, 2022

The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.

Pharmacy 96

Pharmacy Marketing Drugs 96

Drug Patent Watch

MARCH 4, 2022

This chart shows the drugs with the most patents in United Kingdom. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in United Kingdom? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

ProRelix Research

FEBRUARY 27, 2022

The World Health Organization (WHO) defines clinical trials as a type of research that studies new tests and treatments and evaluates their effects on human health outcomes (1). Clinical trials […]. The post Clinical Trial Approval Process in Australia appeared first on ProRelix Research.

Clinical Trials 52

Clinical Trials Trials Treatment Research 52

The Pharma Data

MARCH 3, 2022

Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for prevention of RSV-associated lower respiratory tract illness in infants from birth up to six months of age by active immunization of pregnant women.

Virus 52

Virus Vaccine Clinical Trials Trials 52

Atomwise Blog

FEBRUARY 28, 2022

Atomwise scientists are adapting machine learning models to make predictions about a class of drug compounds that has been challenging to study.

Drugs 52

Drugs 52

Drug Patent Watch

MARCH 4, 2022

Annual Drug Patent Expirations for YUPELRI Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent for Mylan Ireland drug YUPELRI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug & Device Law

MARCH 3, 2022

In the coming weeks, there are sure to be many articles looking at what Judge Brown Jackson has written and what that might suggest about the future jurisprudence of the United States Supreme Court if she is confirmed. We will not predict what will happen in confirmation. We will, however, weigh in on what Judge Brown Jackson—one day she may earn a KBJ moniker as a nod to RBG, but we will resist that for now—has written in our space.

Production 59

Production FDA Drugs Government 59

The Pharma Data

MARCH 3, 2022

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an initial donation of essential medicines to Ukraine. Roche vehemently condemns the violent invasion of the country. Roche is working diligently to support the country and people of Ukraine with medical products in accordance with Roche’s overall mission and announced today that we are donating 150,000 packages of Rocephin, a critical antibiotic used to treat the symptoms of many kinds of bacterial infections and listed on the World Health Orga

Clinical Trials 52

Clinical Trials Packaging Laboratories Pharmaceuticals 52

Drug Patent Watch

MARCH 3, 2022

Annual Drug Patent Expirations for ZYNRELEF+KIT Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Heron Theraps drug ZYNRELEF KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 3, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

MARCH 3, 2022

Annual Drug Patent Expirations for LIVMARLI Livmarli is a drug marketed by Mirum and is included in one NDA. The generic ingredient in LIVMARLI is maralixibat chloride. Additional details are…. The post New patent for MIRUM drug LIVMARLI appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

MARCH 3, 2022

Kelly Gast appointed as new Chief Financial Officer, effective April 1, 2022 / Frank Terhorst to lead new team combining Strategy with Sustainability & Public Affairs, effective March 1, 2022. Bayer today announced changes in the leadership team of its Crop Science division, with Kelly Gast assuming the position of Chief Financial Officer (CFO) from Michael A.

Science 52

Science Production 52

Drug Patent Watch

MARCH 2, 2022

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Pharmaceuticals 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent expiration for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are twenty-three patents…. The post New patent expiration for Astrazeneca Ab drug BYDUREON appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for BYDUREON+BCISE Bydureon Bcise is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are fifteen…. The post New patent expiration for Astrazeneca Ab drug BYDUREON BCISE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for SAFYRAL Safyral is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are three patents…. The post New patent expiration for Bayer Hlthcare drug SAFYRAL appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for BEYAZ Beyaz is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from two suppliers. There are four patents…. The post New patent expiration for Bayer Hlthcare drug BEYAZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

BYDUREON PEN (exenatide synthetic) Astrazeneca ab Patent: 7,223,440 Expiration: Mar 3, 2022 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact…. The post Drug Patent Expirations for the Week of February 27, 2022 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Pharmaceuticals 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for VALTOCO Valtoco is a drug marketed by Neurelis Inc and is included in one NDA. There are five patents protecting this drug. VALTOCO drug price…. The post New patent for Neurelis Inc drug VALTOCO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for TAVALISSE Tavalisse is a drug marketed by Rigel Pharms Inc and is included in one NDA. There are fourteen patents protecting this drug. This drug…. The post New patent for Rigel Pharms drug TAVALISSE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 2, 2022

Annual Drug Patent Expirations for SILENOR Silenor is a drug marketed by Currax and is included in one NDA. It is available from three suppliers. There are fourteen patents protecting…. The post New patent for Currax drug SILENOR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

MARCH 1, 2022

This chart shows the patent expirations for tablet dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Tablet dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs 52

The Pharma Data

MARCH 1, 2022

Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. In conjunction with the rights reacquisition by Affinivax, ASP3772 will be renamed AFX3772.

Vaccine 52

Vaccine Clinical Trials FDA Therapies 52

The Pharma Data

MARCH 1, 2022

– Expands AbbVie’s neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies – Novel mechanism will be evaluated for the potential to mitigate synaptic dysfunction associated with cognitive deficits across a range of neuropsychiatric and neurodegenerative disorders.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52